Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients

Kishimoto, 1995, Interleukin-6 family of cytokines and gp130, Blood, 86, 1243, 10.1182/blood.V86.4.1243.bloodjournal8641243 Assier, 2010, Interleukin-6: from identification of the cytokine to development of targeted treatments, Joint Bone Spine, 77, 532, 10.1016/j.jbspin.2010.07.007 Yao, 2014, Targeting interleukin-6 in inflammatory autoimmune diseases and cancers, Pharmacol Ther, 141, 125, 10.1016/j.pharmthera.2013.09.004 Neurath, 2011, IL-6 signaling in autoimmunity, chronic inflammation-associated cancer, Cytokine Growth Factor Rev, 22, 83, 10.1016/j.cytogfr.2011.02.003 Tilg, 1997, IL-6 and APPs: anti-inflammatory and immunosuppressive mediators, Immunol Today, 18, 428, 10.1016/S0167-5699(97)01103-1 Tilg, 1994, Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55, Blood, 83, 113, 10.1182/blood.V83.1.113.113 Jones, 1999, Autoimmunity, 31, 117, 10.3109/08916939908994055 Gröndal, 2000, Cytokine production, serum levels and disease activity in systemic lupus erythematosus, Clin Exp Rheumatol, 18, 565 Eilertsen, 2011, Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus, Lupus, 20, 607, 10.1177/0961203310392432 Peterson, 1996, Serum and urinary interleukin-6 in systemic lupus erythematosus, Lupus, 5, 571, 10.1177/096120339600500603 Li, 2006, Urinary biomarkers in lupus nephritis, Autoimmun Rev, 5, 383, 10.1016/j.autrev.2005.10.006 Hirohata, 1990, Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement, Arthritis Rheum, 33, 644, 10.1002/art.1780330506 Nielepkowicz-Goździńska, 2013, Exhaled cytokines in systemic lupus erythematosus with lung involvement, Pol Arch Med Wewn, 123, 141 Malide, 1995, Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients, Hum Pathol, 26, 558, 10.1016/0046-8177(95)90253-8 Kuroiwa, 1999, CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms, J Immunol, 163, 2168, 10.4049/jimmunol.163.4.2168 Azkalany, 2012, Clinical significance of serum TNFα and -308 G/A promoter polymorphism and serum Il-6 and -174 G/C promoter polymorphism in systemic lupus erythematosus patients, Egypt Rheumatol, 34, 119, 10.1016/j.ejr.2012.05.003 Tackey, 2004, Rationale for interleukin-6 blockade in systemic lupus erythematosus, Lupus, 13, 339, 10.1191/0961203304lu1023oa Ogata, 2012, Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions, Int J Rheumatol, 2012, 10.1155/2012/946048 Illei, 2010, Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study, Arthritis Rheum, 62, 542, 10.1002/art.27221 Petri, 2012, Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 64, 2677, 10.1002/art.34473 Liang, 1989, Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus, Arthritis Rheum, 32, 1107, 10.1002/anr.1780320909 Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 Studnicka-Benke, 1996, Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus, Br J Rheumatol, 35, 1067, 10.1093/rheumatology/35.11.1067 Willis, 2012, Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort, Lupus, 21, 830, 10.1177/0961203312437270 Mok, 2013, Hepcidin, interleukin-6 and anemia of chronic inflammation in systemic lupus erythematosus, Ann Rheum Dis, 72, A268 Cigni, 2014, Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus, J Invest Med, 62, 825, 10.2310/JIM.0000000000000085 Sinicato, 2014, Obesity and cytokines in childhood-onset systemic lupus erythematosus, J Immunol Res, 2014, 10.1155/2014/162047 Atta, 2015, Higher level of IL-6 in Jaccoud’s arthropathy secondary to systemic lupus erythematosus: a perspective for its treatment?, Rheumatol Int, 35, 167, 10.1007/s00296-014-3069-0 Emilie, 1996, Cytokines and lupus, Ann Med Interne (Paris), 147, 480 Davas, 1999, Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus, Clin Rheumatol, 18, 17, 10.1007/s100670050045 Boehme, 2000, Serum thrombomodulin – a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity, Clin Exp Immunol, 119, 189, 10.1046/j.1365-2249.2000.01107.x Brugos, 2012, Serum and urinary cytokine levels of SLE patients, Pharmazie, 67, 411 Tsai, 2000, Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis, Nephron, 85, 207, 10.1159/000045663 Takemura, 1994, Cellular localization of inflammatory cytokines in human glomerulonephritis, Virchows Arch, 424, 459, 10.1007/BF00191429 Yu, 2001, Anti-dsDNA antibody up-regulates interleukin 6, but not cyclo-oxygenase, gene expression in glomerular mesangial cells: a marker of immune-mediated renal damage?, Inflamm Res, 50, 12, 10.1007/s000110050718 Costedoat-Chalumeau, 2014, Hydroxychloroquine: a multifaceted treatment in lupus, Presse Med, 43, e167, 10.1016/j.lpm.2014.03.007 Tishler, 1999, Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers, Ann Rheum Dis, 58, 253, 10.1136/ard.58.4.253 Sperber, 1993, Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells, J Rheumatol, 20, 803 Silva, 2013, Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients, Clinics (Sao Paulo), 68, 766, 10.6061/clinics/2013(06)07